133 related articles for article (PubMed ID: 11496467)
1. The pharmaceutical situation in the Philippines.
Hartigan-Go K
Aust Health Rev; 2001; 24(2):25-31. PubMed ID: 11496467
[No Abstract] [Full Text] [Related]
2. Some drugs more equal than others: pseudo-generics and commercial practice.
Probyn AJ
Aust Health Rev; 2004 Nov; 28(2):207-17. PubMed ID: 15527401
[TBL] [Abstract][Full Text] [Related]
3. Drugs: budget busters or cost cutters in future health care?
Egger E
Health Care Strateg Manage; 1999 Mar; 17(3):1, 22-3. PubMed ID: 10351640
[No Abstract] [Full Text] [Related]
4. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
Sinha MS; Curfman GD; Carrier MA
JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
[No Abstract] [Full Text] [Related]
5. Australian drugs scheme threatens free-trade talks.
Fickling D
Lancet; 2004 Jan; 363(9405):299. PubMed ID: 14753208
[No Abstract] [Full Text] [Related]
6. The market for pharmaceuticals.
Bergenheim K; Braun U
Dev Health Econ Public Policy; 1998; 7():187-208. PubMed ID: 10538829
[No Abstract] [Full Text] [Related]
7. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
8. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
Adams J
N Z Bioeth J; 2003 Oct; 4(3):22-3. PubMed ID: 15597478
[No Abstract] [Full Text] [Related]
9. And on the cover of the guide were two words in red--don't panic.
Harvey R
Aust Health Rev; 2001; 24(2):15-20. PubMed ID: 11496457
[No Abstract] [Full Text] [Related]
10. Funding arrangements for pharmaceuticals: can economic evaluation promote efficiency?
Viney R
Aust Health Rev; 2001; 24(2):21-4. PubMed ID: 11496466
[No Abstract] [Full Text] [Related]
11. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs.
Cahn LJ
Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372
[No Abstract] [Full Text] [Related]
12. New prescription for the Spanish drug sector: fighting against public deficit without wasting ammunition.
Antoñanzas F; Gómez P
Pharmacoeconomics; 2010; 28(11):977-80. PubMed ID: 20936881
[No Abstract] [Full Text] [Related]
13. Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else.
Dalton A
Aust Health Rev; 2001; 24(2):7-14. PubMed ID: 11496474
[No Abstract] [Full Text] [Related]
14. Global Generic Medicines--Health Network Communications' Second Annual Summit.
Burck B
IDrugs; 2008 May; 11(5):328-30. PubMed ID: 18465671
[No Abstract] [Full Text] [Related]
15. The response to health care reform by the pharmaceutical industry.
Krulwich AS
Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
[No Abstract] [Full Text] [Related]
16. Who's really raising drug prices?
Zagorin A
Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
[No Abstract] [Full Text] [Related]
17. Prescription-drug coupons--no such thing as a free lunch.
Ross JS; Kesselheim AS
N Engl J Med; 2013 Sep; 369(13):1188-9. PubMed ID: 23984672
[No Abstract] [Full Text] [Related]
18. Implications of the Australian guidelines for the United States.
Freund DA; Evans D; Henry D; Dittus R
Health Aff (Millwood); 1992; 11(4):202-6. PubMed ID: 1483641
[No Abstract] [Full Text] [Related]
19. Perspectives. Drug formularies pose legal threat to providers.
Moskowitz DB
Faulkner Grays Med Health; 1995 Feb; 49(6):suppl 1-4. PubMed ID: 10139750
[No Abstract] [Full Text] [Related]
20. Regulating manufacturer-affiliated communication in the information age.
Schulman KA; Abernethy DR; Rathore SS; Woosley RL
Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
[No Abstract] [Full Text] [Related]
[Next] [New Search]
